Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
09/18/2017 09/19/2017 09/20/2017 09/21/2017 09/22/2017 Date
65.99(c) 65.95(c) 65.79(c) 65.6(c) 65.13(c) Last
10 543 216 7 009 284 9 450 016 5 968 693 7 378 603 Volume
-0.26% -0.06% -0.24% -0.29% -0.72% Change
More quotes
Financials ($)
Sales 2017 40 323 M
EBIT 2017 13 721 M
Net income 2017 5 623 M
Debt 2017 7 139 M
Yield 2017 2,89%
Sales 2018 41 318 M
EBIT 2018 14 652 M
Net income 2018 9 113 M
Debt 2018 7 348 M
Yield 2018 2,98%
P/E ratio 2017 32,52
P/E ratio 2018 19,43
EV / Sales2017 4,58x
EV / Sales2018 4,48x
Capitalization 178 B
More Financials
Company
Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products.It operates through the following segments: Pharmaceutical, Animal Health, Alliances and Healthcare Services.The Pharmaceutical... 
Sector
Pharmaceuticals
Calendar
10/17Presentation
More about the company
Surperformance© ratings of Merck and Company
Trading Rating : Investor Rating :
More Ratings
Latest news on MERCK AND COMPANY
09/22 MERCK AND : FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Previously ..
09/22 MERCK AND : Drug Makers Stocks on Investors' Radar -- Alliqua BioMedical, Immune..
09/21 MERCK AND : MSD`s Keytruda wins new bladder cancer indication in Europe
09/19 MERCK AND : Pro Baseball Hall of Famer and Cancer Survivor Mike Schmidt Joins Me..
09/14 MERCK AND : Rigontec Acquired by MSD
09/14 MERCK AND COMPANY : ex-dividend day
09/12 NOW AVAILABLE IN CANADA : ISENTRESS® HD (raltegravir), a New Once-Daily Option, ..
09/12 MERCK AND : KEYTRUDA Plus Pemetrexed and Carboplatin Demonstrated Continued Bene..
09/12 MERCK AND : KEYTRUDA Continues to Show Overall Survival Benefit over Chemotherap..
09/12 MERCK AND : Updated Data for Merck's KEYTRUDA in Patients with Advanced Gastric ..
More news
Sector news : Pharmaceuticals - NEC
09/22DJCorrection to Sept. 7 Harvey Rebuilding Article
09/22 Korea tensions keep European shares in check before Germany vote
09/22 Bettencourt death stirs speculation about L'Oreal ownership
09/22 China online insurer ZhongAn prices Hong Kong IPO at top end, raises $1.5 bil..
09/21DJPFIZER : Files Antitrust Lawsuit Against J&J -- WSJ
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on MERCK AND COMPANY 
MERCK & CO., INC. - 2013
A resistance as obstacle
SELL
More Strategies
Latest Tweets
09/22$MRK: Merck announces that the FDA has approved KEYTRUDA for the treatment of.. 
09/22BRIEF-Merck says FDA approves Keytruda(pembrolizumab) for previously treated .. 
09/22FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Previously Treated Patient.. 
09/22FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Previously Treated Patient.. 
09/22$MRK Merck receives FDA approval for Keytruda for Treatment of Gastro Adenoca.. 
More tweets
Qtime:258
News from SeekingAlpha
09/22 FDA OKs Merck's Keytruda for gastric cancer
09/22 REDHILL BIOPHARMA : Highly De-Risked And Undervalued With A Deep Pipeline
09/21 FDA's Woodcock says clinical trials system "broken"
09/21 Mirati Brings Hope With Its Stellar Performance
09/21 Hold On To Zoetis In 2017
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 70,1 $
Spread / Average Target 7,6%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY11.75%177 633
JOHNSON & JOHNSON15.63%353 617
NOVARTIS11.88%223 850
ROCHE HOLDING LTD.6.19%221 926
PFIZER10.81%214 206
SANOFI9.06%126 655